A Phase 2, Single Dose, Open-Label, Exploratory Study to Investigate the Safety and Efficacy of OTL38 Injection for Intraoperative Imaging of Folate Receptor Positive Lung Nodules
Phase of Trial: Phase II
Latest Information Update: 26 Nov 2017
At a glance
- Drugs Folate-fluorescein isothiocyanate conjugate (Primary)
- Indications Lung cancer
- Focus Diagnostic use
- Sponsors On Target Laboratories
- 05 Jun 2017 Planned End Date changed from 1 Jan 2018 to 1 Mar 2018.
- 05 Jun 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Jan 2018.
- 05 Jun 2017 Status changed from not yet recruiting to recruiting.